SEQUENT SCIENTIFIC LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 103.5 INR | -.--% |
|
-5.52% | -9.09% |
| 16/05 | Sequent Scientific Limited Seeks M&A | CI |
| 16/05 | Transcript : Sequent Scientific Limited, Q4 2024 Earnings Call, May 16, 2024 |
| Sales 2022 | 1.41TCr 17Cr | Sales 2023 | 1.42TCr 17Cr | Capitalization | 1.8TCr 22Cr |
|---|---|---|---|---|---|
| Net income 2022 | 41Cr 49.51L | Net income 2023 | -121.2Cr -1.45Cr | EV / Sales 2022 | 2.55 x |
| Net Debt 2022 | 305.97Cr 3.67Cr | Net Debt 2023 | 401.98Cr 4.82Cr | EV / Sales 2023 | 1.55 x |
| P/E ratio 2022 |
81.1
x | P/E ratio 2023 |
-14.9
x | Employees | 1,301 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 45.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sequent Scientific Limited
More recommendations
| 1 week | -5.52% | ||
| 1 month | -16.23% | ||
| 3 months | -18.34% | ||
| 6 months | -16.34% | ||
| Current year | -9.09% |
1 week
102.45
110.45
1 month
102.45124.65
Current year
102.45155.45
1 year
72.65155.45
3 years
61.80336.40
5 years
52.00336.40
10 years
42.45336.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 11/22/11 | |
Saurav Bhala
DFI | Director of Finance/CFO | - | 06/11 |
Prasad Lad
ADM | Chief Administrative Officer | - | 01/14/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Neeraj Bharadwaj
BRD | Director/Board Member | 55 | 17/20/17 |
| Chairman | 76 | 25/20/25 | |
| Director/Board Member | 64 | 25/20/25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 112 M€ | +4.61% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 103.5 | -.--% | 32,416 |
| 30/24/30 | 103.5 | -1.48% | 38,987 |
| 29/24/29 | 105 | +0.53% | 24,067 |
| 28/24/28 | 104.5 | -1.74% | 62,084 |
| 27/24/27 | 106.4 | -2.92% | 63,579 |
Delayed Quote Bombay S.E., May 31, 2024 at 03:30 pm IST
More quotes
SeQuent Scientific Limited is an India-based animal health company. The Company provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The Company operates through the pharmaceuticals segment. The Company is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. Its subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q1 2025 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -9.09% | 31Cr | |
| +40.73% | 74TCr | |
| +32.83% | 60TCr | |
| -6.30% | 35TCr | |
| +15.15% | 32TCr | |
| +4.05% | 28TCr | |
| +15.00% | 24TCr | |
| -5.52% | 21TCr | |
| +6.17% | 16TCr | |
| -0.45% | 16TCr |
- Stock Market
- Equities
- SEQUENT Stock
